MicroRNA signature in patients with hepatocellular carcinoma associated with type 2 diabetes
- MicroRNA signature in patients with hepatocellular carcinoma associated with type 2 diabetes
- 판철호; 무스타파 바드르; Marwa Anwar Mohamed; Marwa Ahmed Madkour; Mohammed Mohammed Shamseya; Noha Mahmoud Issa; Ahmed Noah Badr; Doaa Ahmed Ghareeb
- MicroRNA; Hepatocellular carcinoma; Type 2 diabetes; Nonalcoholic fatty liver disease
- Issue Date
- WORLD JOURNAL OF GASTROENTEROLOGY
- VOL 25, NO 42-6341
Nonalcoholic steatohepatitis-related cirrhosis is one of the liver complications in type 2 diabetes mellitus (T2DM) and reported to be a risk factor for developing hepatocellular carcinoma (HCC). A reliable screening biomarker of liver cirrhosis (LC) and HCC among T2DM patients is important to reduce the morbidity and mortality of this disease. MicroRNA (miRNA) is considered a key player in HCC and T2DM, and it might be a hidden culprit in diabetes-associated HCC, making it a promising reliable prognostic tool.
To investigate the signature of serum miRNAs as early biomarkers for the screening of HCC among diabetic patients.
Expression profiles of miRNAs in serum samples of diabetic LC and diabetic HCC patients were assessed using Illumina sequencing; then, RT-qPCR was used to validate significantly altered miRNAs between the two groups. Candidate miRNAs were tested in serum samples of 200 T2DM patients, 270 LC patients, 200 HCC patients, and 225 healthy control subjects. Additionally, receiver operating characteristic (ROC) analysis, with area under the curve (AUC), was
performed to assess the diagnostic performance of the screened miRNAs for discriminating HCC from LC and nonmalignant patients (LC + T2DM).
Expression of the sequenced miRNAs in serum was different in HCC vs LCpositive T2DM patients. Two miRNAs (miR-34a, miR-221) were significantly upregulated and five miRNAs (miR-16, miR-23-3p, miR-122-5p, miR-198, miR-199a-3p) were significantly down-regulated in HCC compared to LC patients. Analysis of ROC curve demonstrated that the combination of these seven miRNAs can be used as a reliable biomarker for detection of HCC in diabetic patients, as it could identify HCC with high diagnostic accuracy in diabetic LC patients (AUC = 0.993) and in diabetic nonmalignant patients (AUC = 0.961).
This study validates a panel of serum miRNAs that can be used as a reliable
- Appears in Collections:
- KIST Publication > Article
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.